Arbutus's Imdusiran Combined With Short-Term Interferon Successfully Maintains Undetectable HBsAg Levels, Essential For A Functional Cure Of HBV
$ABUS
Biotechnology: Pharmaceutical Preparations
Health Care
- At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100% of these patients 24 weeks after completing imdusiran and IFN treatment
- Of the patients who have stopped all therapy, six still have undetectable levels of HBsAg and HBV DNA, with two of these patients reaching 12 weeks off all therapy
- All six patients have seroconverted and have high titers of anti-HBsAg antibodies
- These new Phase 2a data were presented at the European Association for the Study of the Liver (EASL) Congress 2024